#ESCCongress#HOTLINE 2
MAPLE-HCM w/ impressive results presented by @dr_pavia
Are we headed to CMI as 1st line therapy for LVOTO⁉️
Aficamten was superior to Metoprolol in the primary endpoint of ⬆️pVO2 and ALL sec endpoints (NYHA, KCCQ, NTproBNP, LVOTO).
Enhorabuena Pablo!
#ESCCongress HOTLINE 2️⃣
ODYSSEY-HCM failed to reach its primary endpoint of increase in KCCQ and peak VO2 in non-obstructive #HCM
Subgroup analysis suggest potential benefit
▶️ younger patients
▶️ less advanced disease and shorter duration of disease
▶️ less diastolic dysfunction
What do we know about using beta blockers in HFpEF? Turns out not a whole lot. Need more definitive withdrawal RCTs to answer this fundamental question jamanetwork.com/journals/jam…
The 2025 Heart Failure Symposium is around the corner, and we are proud to announce that the course has been officially endorsed by the Heart Failure Society of America. Join us on May 10: bit.ly/2025-HF-Symposium
Super fun heart failure consult week at Parkland with trainees at all levels! Impressed by the thoughtful care delivered by these fantastic future cardiologists! @ayeeshik@GailPetersonMD@UTSWCardfellow@UTSWIMchief
Will this be the silver bullet to end with EMB as the gold-standard for post-HT monitoring? Results from the #SHORE registry show that the combination of GEP dd-cfDNA is better associated with post-HT outcomes than EMB. Congrats all the authors for this amazing work #ishlt2024
Excited to share findings from the #DanGer trial #ACC24 from Jacob Moller @CardioNerds#cardiogenicshock#ImpellaCS
🫀international, multicenter, randomized trial
🫀patients with STEMI and cardiogenic shock were assigned to Impella CP vs standard care only #NEJM